Who we are
We develop and manufacture lentiviral vectors as a European leader working under both EMA and FDA standards. The lentiviral vectors produced by VIVEbiotech are administered both ex-vivo and in-vivo to treat a range of disorders, including haematological and solid cancers, and rare diseases.
We are a Contract Development and Manufacturing Organization (CDMO) with over 40 biotech companies worldwide that have placed their trust in us.
A solid project with its own personality
Our roots are 100% Guipuzcoan. Since 2015 we have spearheaded the creation of an ecosystem in our region specialized in health-related biotechnology aimed at personalized precision medicine.
Our stable international clients and large-scale projects allow us to consolidate our structure and continue to grow sustainably, positioning our company and our region at the forefront of the medicine of the future on a global level.
2015 - Today
US, European, Asian and Australian customers
Compliance with EMA and FDA regulations
Expansion plan completed in 2021
One of the few companies fully focused on lentiviral vectors
Timely slot availability
Project with a future
These are exciting times in the world of biotechnology and health, with realistic expectations for cures for many pathologies. VIVEbiotech is one of the players making this possible. In 2021 we opened a new facility with state-of-the-art equipment and capacity for clinical and commercial production phases as a stepping stone to VIVEbiotech's future strategic goals.